U.S. Markets closed
  • S&P 500

    +0.57 (+0.01%)
  • Dow 30

    +8.77 (+0.03%)
  • Nasdaq

    -33.88 (-0.30%)
  • Russell 2000

    -2.96 (-0.17%)
  • Crude Oil

    +0.46 (+0.42%)
  • Gold

    +3.90 (+0.21%)
  • Silver

    -0.03 (-0.13%)

    -0.0026 (-0.2429%)
  • 10-Yr Bond

    -0.0680 (-2.38%)
  • Vix

    +0.08 (+0.27%)

    +0.0020 (+0.1587%)

    +0.0560 (+0.0438%)

    -575.86 (-1.92%)
  • CMC Crypto 200

    -23.03 (-3.42%)
  • FTSE 100

    +87.24 (+1.19%)
  • Nikkei 225

    +336.19 (+1.27%)

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Nano-X Imaging (NNOX) Investors to DEC. 6TH FINAL DEADLINE in Securities Class Action, Urges Investors with Significant Losses to Contact Firm’s Attorneys

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, CA / ACCESSWIRE / December 5, 2021 / Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ:NNOX) investors with significant losses to submit your losses now.

Class Period: June 17, 2021 - Aug. 18, 2021

Lead Plaintiff Deadline: Dec. 6, 2021


Contact An Attorney Now:NNOX@hbsslaw.com


Nano-X Imaging Ltd. (NNOX) Securities Fraud Class Action:

Nano-X, a digital X-ray company, is developing the "Nanox.ARC," an imaging system that uses a purportedly novel X-ray source.

On June 17, 2021, Nano-X intrigued investors when it announced that it had submitted a 510(k) submission to the FDA to demonstrate the Nanox.ARC is marketed as safe and effective and substantially equivalent to a legally marketed device.

The litigation alleges that Defendants misled investors concerning the 510(k) submission for Nanox.ARC. Specifically, while touting Nanox.ARC's regulatory and commercial prospects, Defendants concealed: (i) Nano-X's 510(k) application for the Nanox.ARC was deficient; (ii) accordingly, it was unlikely that the FDA would approve the 510(k) application for the Nanox.ARC in its current form; and (iii) as a result, Nano- X had overstated Nanox.ARC's regulatory and commercial prospects.

The truth emerged on Aug. 19, 2021, when Nano-X reported that the Company received a request for additional information from the FDA concerning Nano-X's 510(k) application for the Nanox.ARC, and that the submission file is placed on hold pending Nano-X's complete response to the FDA's list of deficiencies within 180 days.

On this news, Nano-X's ordinary share price fell $2.25 per share, or 9.5%, to close at $21.43 per share on Aug. 19, 2021.

"We're focused on investors' losses and proving Nano-X mispresented Nanox.ARC's regulatory and commercial prospects," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Nano-X Imaging and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Nano-X Imaging should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email NNOX@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on accesswire.com: